Viatris sales interviews test whether candidates understand how selling complex generics and off-patent branded pharmaceuticals differs from branded specialty pharma sales – where institutional channel access for generic products depends on GPO contract compliance and formulary positioning at health system pharmacy committees rather than individual prescriber detailing, where the gross-to-net gap between wholesale acquisition cost and net average selling price after Medicaid rebates, PBM chargebacks, and distributor fees determines actual product economics in ways that sales teams must understand when evaluating whether a PBM's formulary positioning offer is commercially acceptable, and where EpiPen's pricing history created institutional memory among payers and healthcare buyers that commercial teams must navigate when presenting Viatris as a reliable partner for patient access programs. Sales at Viatris spans PBM formulary access negotiation for off-patent branded products (where securing Tier 2 or Tier 3 placement for branded products like EpiPen, Celebrex, and Dymista requires offering rebate contracts to pharmacy benefit managers that bring net prices into competitive alignment with generic alternatives while maintaining enough revenue margin to justify branded product detailing investment), GPO and IDN contracting for generic portfolio access (where hospital and integrated delivery network formulary access for Viatris's generic portfolio is secured through group purchasing organization master contracts that establish pricing tiers, compliance requirements, and eligibility across hundreds of member health systems simultaneously), specialty pharmacy channel management for complex products (where Yupelri's revefenacin COPD treatment requires specialty pharmacy distribution with patient adherence programs, prior authorization support, and hub services that differ fundamentally from retail pharmacy channel management), and institutional versus retail channel coordination (where a branded product's market access strategy must coordinate formulary positioning across PBMs serving commercial insurance markets, state Medicaid agencies with mandatory rebate programs under OBRA '90, and the 340B covered entity hospital system channel where ceiling price rules limit net revenue per unit).
Start your free Viatris Sales practice session.
What interviewers actually evaluate
GPO Channel Selling, Gross-to-Net Economics, and Formulary Access Strategy
Viatris sales interviews probe whether candidates understand how pharmaceutical channel selling differs from general healthcare B2B sales in the gross-to-net complexity (a Viatris branded product with a $500 WAC may generate less than $200 in net revenue after Medicaid best price rebates, commercial PBM rebates, 340B ceiling price obligations, and distributor chargebacks – where the commercial team's job is to secure market access at formulary positions that generate sufficient net revenue to justify the product's manufacturing cost, patient support investment, and detailing expense, and where a PBM offering formulary placement in exchange for a higher rebate may or may not improve the product's profitability depending on the rebate obligation it creates across the entire payer mix), the institutional contracting versus prescriber detailing trade-off (generic pharmaceutical selling is primarily an institutional contracting exercise where GPO relationships, health system formulary committee presentations, and pharmacy buyer negotiations determine which generic products appear on formulary and get dispensed without prescriber input – while branded off-patent products like EpiPen require both institutional formulary access and prescriber engagement for allergy and emergency medicine physicians who influence treatment decisions in a competitive market with generic epinephrine alternatives), and the EpiPen market access complexity (EpiPen's pricing history created payer resistance to Viatris's branded EpiPen that commercial teams must address through patient assistance programs, Mygefbag program access, and formulary concessions that make EpiPen accessible to patients despite the gross-to-net obligations that the pricing history created).
The international market selling dimension adds a sales complexity that domestic branded pharmaceutical selling does not address: Viatris's former Upjohn portfolio includes branded off-patent products with significant market positions in emerging markets including Asia-Pacific, Latin America, and Middle East and Africa where branded generic selling requires building relationships with national health authority formulary bodies, local distributor networks, and hospital procurement offices under regulatory and commercial frameworks that differ from US market access strategies.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| PBM formulary negotiation and gross-to-net economics understanding | Do you understand how to negotiate PBM formulary access for Viatris branded products – how to evaluate a PBM's proposed rebate contract for EpiPen that offers preferred Tier 2 placement in exchange for a rebate that improves EpiPen's formulary position over generic alternatives, what the net revenue calculation looks like when the PBM rebate obligation is applied across the commercial plan lives the PBM manages plus the Medicaid best price implications of any commercial rebate that lowers the effective net price, and how to determine the minimum formulary position and maximum rebate that makes the PBM access deal commercially acceptable for Viatris? We flag sales answers that treat PBM negotiation as a price discount discussion without engaging with the gross-to-net impact analysis and best price Medicaid implications that make pharmaceutical formulary negotiation financially complex. | Net revenue calculation after PBM and Medicaid rebates, best price implication assessment, minimum acceptable formulary position |
| GPO contracting and health system formulary access for generic portfolio | Can you describe how to develop Viatris's generic portfolio contracting strategy with a major GPO like Vizient or Premier – what compliance requirements GPO members must meet to receive contracted pricing tiers, how to structure a competitive bid that positions Viatris's generic products against competing generic manufacturers who are offering aggressive pricing to win compliant purchasing commitments, and how to manage the relationship with individual health system pharmacy directors who influence whether their institution achieves the GPO compliance thresholds that unlock contracted pricing? We score whether your GPO contracting approach engages with the compliance tier structure and individual health system relationship management that determines actual GPO contract pull-through beyond the master contract terms. | GPO compliance tier requirements, competitive generic bid strategy, health system pharmacy director relationship management |
| Specialty pharmacy channel management for Yupelri COPD treatment | Do you understand how to manage Viatris's specialty pharmacy channel for Yupelri – how to select and contract with specialty pharmacy partners who have respiratory therapy expertise and the patient adherence infrastructure that COPD patients with complex medication regimens require, what the hub services model includes for prior authorization support and patient financial assistance that make Yupelri accessible despite commercial insurance prior authorization requirements, and how to measure specialty pharmacy partner performance against fill rate, abandonment rate, and patient persistence metrics that determine whether the specialty pharmacy channel is supporting Yupelri's market share objectives? We detect sales answers that treat specialty pharmacy as standard distribution channel management without engaging with the hub services, prior authorization support, and patient adherence program elements that make specialty product commercial success dependent on specialty pharmacy partner capabilities. | Specialty pharmacy partner selection criteria, hub services design for COPD patients, specialty channel performance metrics |
| EpiPen patient access and market positioning after pricing controversy | Can you describe how to develop the commercial access strategy for EpiPen in the post-pricing-controversy environment where payers and PBMs have created formulary advantages for generic epinephrine auto-injectors – what Viatris's patient assistance programs provide for patients who cannot afford EpiPen at commercial insurance cost-sharing levels, how to position EpiPen's device quality and training support advantages relative to generic alternatives for prescribers in allergy and emergency medicine who influence patient outcomes through device selection, and how to develop payer relationships that acknowledge the pricing history while presenting Viatris's current market access commitment as genuine rather than defensive? We flag sales answers that ignore EpiPen's pricing history or present formulary access negotiation for EpiPen as equivalent to a standard branded product negotiation without engaging with the payer credibility challenge that the pricing controversy created for Viatris's commercial relationships. | Patient assistance program design, EpiPen device advantage positioning, payer relationship credibility management |
How a session works
Step 1: Choose a Viatris sales scenario – PBM formulary negotiation and gross-to-net economics for branded off-patent products, GPO contracting and health system formulary access for the generic portfolio, specialty pharmacy channel management for Yupelri, or EpiPen patient access strategy and market positioning.
Step 2: The AI interviewer asks realistic Viatris-style questions: how you would evaluate and respond to a major PBM's proposal to move EpiPen from its current Tier 3 position to Tier 2 preferred in exchange for a 45% rebate on EpiPen's WAC – including how to calculate the net revenue impact of the 45% rebate across the PBM's commercial plan lives, what the Medicaid best price implication is if the commercial rebate lowers EpiPen's effective net price below the current Medicaid AMP-based best price, and how to negotiate a contract structure that achieves preferred formulary access while limiting the rebate obligation's impact on Medicaid pricing; how you would develop the contracting strategy for Viatris's metformin and other generic portfolio products at a Vizient contract renewal – including how to structure the compliance tier requirements that reward high-compliance health system members with the deepest pricing tiers, what the competitive analysis is for the Vizient tender across alternative generic suppliers including Sun Pharmaceutical and Teva, and how to prioritize which generic products in Viatris's portfolio to compete aggressively for versus which to defend at current pricing levels; or how you would develop the reimbursement access strategy for Yupelri in commercial insurance markets where respiratory agents typically face prior authorization requiring documentation of prior LAMA therapy failure or COPD severity criteria – including what the prior authorization support services Viatris provides through specialty pharmacy partners include, how to train pulmonology office staff on the prior authorization documentation process that maximizes approval rates, and what the patient financial assistance bridge program looks like for patients denied prior authorization who are still initiated on Yupelri.
Step 3: You respond as you would in the actual interview. The system scores your answer on PBM formulary negotiation, GPO contracting, specialty pharmacy management, and EpiPen access strategy.
Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical commercial expertise and what needs stronger gross-to-net analysis or GPO contracting strategy specificity.
Frequently Asked Questions
How does the pharmaceutical gross-to-net gap affect Viatris's commercial strategy?
The gross-to-net gap represents the difference between a pharmaceutical product's wholesale acquisition cost – the list price that manufacturers publish and that retail pharmacies pay before discounts – and the net average selling price that the manufacturer actually receives after mandatory Medicaid rebates, voluntary commercial PBM rebates, distributor service fees, and chargeback adjustments. For Viatris's branded off-patent products like EpiPen and Celebrex, the gross-to-net gap can represent 50-70% of WAC, meaning that commercial teams must negotiate formulary access deals that generate sufficient market share and volume gains to justify the rebate obligations they create. The commercial team's job is understanding which payer access deals improve Viatris's net revenue position by gaining volume at acceptable net prices versus which deals create rebate obligations that exceed the revenue value of the formulary position they purchase.
What are GPO contracts and why are they critical for Viatris's generic portfolio?
Group purchasing organizations like Vizient, Premier, and Intalere aggregate purchasing volume from hundreds of hospital members to negotiate discounted prices from pharmaceutical manufacturers in exchange for compliance commitments – where member hospitals that purchase a specified percentage of their category volume from the contracted manufacturer receive the contracted price tier. For Viatris's generic portfolio, GPO contracts provide access to the institutional pharmacy channel at pricing that reflects the aggregated volume of hundreds of health systems, and GPO contract wins are critical for establishing the distribution pull-through at health system pharmacies that determines generic product market share in the institutional channel. Competing effectively in GPO tenders requires understanding the compliance tier structure, the importance of supply reliability alongside price, and the pharmacy director relationships at key member health systems that influence whether members achieve compliance thresholds.
How did EpiPen's pricing history affect Viatris's commercial position?
Mylan N.V., one of Viatris's predecessor companies, raised EpiPen's price approximately 600% between 2007 and 2016, from approximately $100 for a two-pack to over $600, creating congressional scrutiny, media coverage, and patient access concern that resulted in Mylan's CEO testifying before the Senate. In 2017, Mylan agreed to pay $465 million to resolve DOJ allegations that it had misclassified EpiPen as a branded product for Medicaid rebate purposes rather than paying the higher rebate rate applicable to non-innovator products. The pricing controversy created payer credibility challenges for EpiPen's commercial team, led to PBMs creating formulary advantages for generic epinephrine auto-injectors and authorized generics, and damaged Viatris's reputation with health advocacy organizations that continue to monitor EpiPen's pricing and patient access. Viatris has responded through patient assistance programs including generic EpiPen at lower cost and income-based patient support programs.
What is Yupelri and what makes it a specialty commercial product?
Yupelri (revefenacin) is a once-daily nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of patients with COPD. Unlike most inhaled COPD medications delivered via metered-dose inhaler or dry powder inhaler, Yupelri is delivered via standard jet nebulizer – making it particularly relevant for COPD patients who prefer nebulizer delivery or who cannot effectively use inhaler devices. As a branded respiratory product requiring prior authorization from commercial insurers and Medicare Part D plans, Yupelri requires specialty pharmacy distribution with prior authorization support services, patient assistance programs for financially limited patients, and adherence support programs for COPD patients managing complex multi-drug regimens. The specialty commercial model for Yupelri differs significantly from Viatris's generic portfolio commercial model.
How does Viatris sell in international markets through the former Upjohn franchise?
The Pfizer Upjohn division that Viatris acquired through the 2020 combination brought an extensive international branded generic portfolio across emerging markets including China, Russia, Eastern Europe, Latin America, and Southeast Asia. In these markets, Viatris maintains branded positions for off-patent products like Norvasc (amlodipine), Lyrica (pregabalin), and Celebrex (celecoxib) that compete against generic manufacturers on brand reputation, distribution network, and physician relationships rather than on innovation. The commercial model in emerging markets differs from the US market because many emerging market countries lack the PBM formulary system, and market access often depends on national health authority inclusion on essential medicine lists, hospital procurement committee relationships, and local distributor partnerships that Viatris manages through its regional commercial organizations.
Also practice
- Customer Service
- Product Management
- Marketing
- Finance
- Operations
- People & HR
- Leadership
- Legal & Compliance
One full session free. No account required. Real, specific feedback.
